BioCryst Pharmaceuticals (Nasdaq: BCRX) is looking to Wall Street investors to raise $70 million in additional capital.
In a filing with the SEC, the Durham-based firm with some 40 employees in the Bull City, said the funds would be used for research and development, pre-commercialization of its intravenous influenza treatment called Peramivir, and working capital.
BioCryst is already receiving more than $200 million in federal funding to support development of Peramivir, which is still being tested in clinical trials.
“We may also use a portion of the net proceeds to acquire or invest in businesses, assets, products and technologies that are complementary to our own, although we are not currently contemplating or negotiating any such acquisitions or investments,” BioCryst said in the filing.
Read the SEC filing here..
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.